‘Shattuck Labs, Inc. Reports Positive Initial Data from Phase 1AB Trial of SL-172154 in Frontline HR-MDS and TP53m AML Patients\n\nShattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company, has announced promising initial results from its ongoing Phase 1AB clinical trial of SL-172154 in combination with azacitidine (AZA) in frontline HR-MDS and TP53m AML patients. These results build on the complete dose-escalation data presented at the 65th ASH Annual Meeting on December 11, 2023.\n\nDr. Lini Pandite, MBChB, M.B.A., Chief Medical Officer of Shattuck, stated, “We are pleased to share the initial efficacy data from our dose-expansion cohorts, which demonstrate the potential of SL-172154 beyond what is expected of AZA alone. In the dose-escalation study, we saw a monotherapy response in a heavily pre-treated RR TP53m AML patient, allowing the patient to receive a stem cell transplant and remain disease-free. In the frontline cohorts, we have already observed a promising rate of complete responses in both HR-MDS and TP53m AML patients, and we expect this rate to continue to improve as more data becomes available.”\n\nThe Phase 1AB trial enrolled 14 frontline TP53m AML patients and 22 frontline HR-MDS patients. Initial enrollment was completed in mid-2023, and the study is ongoing. Preliminary data suggest that SL-172154 has an acceptable safety and tolerability profile in combination with AZA.\n\nShattuck will host a conference call and webcast today, December 13, 2023 at 8:00 a.m. ET to discuss the initial data from the Phase 1AB trial. The company has also amended both studies to increase the sample size and plans to provide another update by mid-year 2024.\n\nIn a Shattuck Labs, Inc. has reported positive initial data from its Phase 1AB trial of SL-172154 in frontline HR-MDS and TP53m AML patients.’